Director

Office of Strategic Planning and Discipline Construction

Contact Information

• Office: Room 1223, Researching Building 18

• Email: jianli@ecust.edu.cn

• Office Phone: +86 21 64252584

• Office Fax: +86 21 64252584

Education

• 09/2003-07/2006  Ph.D.  Drug Design, Shanghai Institute of Materia Medica  (SIMM), Chinese Academy of Science (CAS), Shanghai, China

• 09/2000-07/2003  M.S.  Medicinal Chemistry, Shenyang Pharmaceutical University, Shenyang, China

• 09/1996-07/2000  B.E.  Pharmaceutical Chemistry, Shenyang Pharmaceutical University, Shenyang, China

Professional Experience

• 05/2018-now  Professor, Director of Office of Strategic Planning and Discipline Construction, East China University of Science & Technology, Shanghai, China

• 05/2017-05/2018  Professor, Secretary of the Party Committee of School of Pharmacy, East China University of Science & Technology, Shanghai, China

• 09/2015-07/2017  Professor, Vice Dean of School of Pharmacy, East China University of Science & Technology, Shanghai, China

• 09/2011-09/2015  Professor, Director of Department of Pharmaceutical Sciences, School of Pharmacy, East China University of Science & Technology, Shanghai, China

• 03/2011-09/2011  Associate Professor, Director of Department of Pharmaceutical Sciences, School of Pharmacy, East China University of Science & Technology, Shanghai, China

• 12/2006-03/2011  Associate Professor, School of Pharmacy, East China University of Science & Technology, Shanghai, China

• 07/2006-12/2006  Lecturer, School of Pharmacy, East China University of Science & Technology, Shanghai, China

Research Interests

• The secondary development of approved drugs

• Discovery of unknown targets and new derivatives of approved drug probe

• Novel anti-MRSA therapeutic agents targetting on bacterial virulence

Publication

1. Baoli Li^#; Shuaishuai Ni^#; Fei Mao^#; Feifei Chen; Yifu Liu; Hanwen Wei; Wenhua Chen; Jin Zhu; Lefu Lan*; Jian Li*, Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity, Journal of Medicinal Chemistry, 2018, 61(1): 224~250.

2. Yifu Liu^#; Zuoquan Xie^#; Dan Zhao; Jin Zhu; Fei Mao; Shuai Tang; Hui Xu; Cheng Luo; Meiyu Geng; Min Huang*; Jian Li*, Development of the first generation of disulfide-based subtype-selective and potent covalent pyruvate dehydrogenase kinase 1 (PDK1) inhibitors, Journal of Medicinal Chemistry, 2017, 60(6): 2227~2244.

3. Yanli Lu^#; Fei Mao^#; Xiaokang Li; Xinyu Zheng; Manjiong Wang; Qing Xu; Jin Zhu; Jian Li*, Discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs), Journal of Medicinal Chemistry, 2017, 60(12): 5099~5119.

4. Shuaishuai Ni^#; Hanwen Wei^#; Baoli Li^#; Feifei Chen; Yifu Liu; Wenhua Chen; Yixiang Xu; Xiaoxia Qiu; Xiaokang Li; Yanli Lu; Wenwen Liu; Linhao Hu; Dazheng Lin; Manjiong Wang; Xinyu Zheng; Fei Mao; Jin Zhu; Lefu Lan*; Jian Li*, Novel inhibitors of staphyloxanthin virulence factor in comparison with linezolid and vancomycin versus methicillin-resistant, linezolid-resistant, and vancomycin-intermediate staphylococcus aureus infections in vivo, Journal of Medicinal Chemistry, 2017, 60(19): 8145~8159.

5. Weiqiang Lu^#; Feixiong Cheng^#; Wenzhong Yan^#; Xi Li; Xue Yao; Wenqiang Song; Mingyao Liu; Xu Shen; Hualiang Jiang; Jin Chen; Jian Li*; Jin Huang*, Selectivetargeting p53WT lung cancer cells harboring homozygous p53 Arg72 byan inhibitor of CypA, Oncogene, 2017, 36(33): 4719~4731.

6. Feifei Chen^#; Hongxia Di^#; Youxin Wang^#; Qiao Cao; Bin Xu; Xue Zhang; Nana Yang; Guijie Liu; Cai-Guang Yang; Yong Xu; Hualiang Jiang; Fulin Lian; Naixia Zhang; Jian Li*; Lefu Lan*, Small-molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence, Nature Chemical Biology, 2016, 12(3): 174~179.

7. Youxin Wang^#; Feifei Chen^#; Hongxia Di; Yong Xu; Qiang Xiao; Xuehai Wang; Hanwen Wei; Yanli Lu; Lingling Zhang; Jin Zhu; Chunquan Sheng; Lefu Lan*; Jian Li*, Discovery of potent benzofuran-derived diapophytoene desaturase (CrtN) inhibitors with enhanced oral bioavailability for the treatment of methicillin-resistant staphylococcus aureus (MRSA) infections, Journal of Medicinal Chemistry, 2016, 59(7): 3215~3230.

8. Youxin Wang^#; Hongxia Di^#; Feifei Chen; Yong Xu; Qiang Xiao; Xuehai Wang; Hanwen Wei; Yanli Lu; Lingling Zhang; Jin Zhu; Lefu Lan*; Jian Li*, Discovery of benzocycloalkane derivatives efficiently blocking bacterial virulence for the treatment of methicillin-resistant S. aureus (MRSA) infections by targeting diapophytoene desaturase (CrtN), Journal of Medicinal Chemistry, 2016, 59(10): 4831~4848.

9. Wenyi Sun^#; Zuoquan Xie^#; Yifu Liu^#; Dan Zhao^#; Zhixiang Wu; Dadong Zhang; Hao Lv; Shuai Tang; Nan Jin; Hualiang Jiang; Minjia Tan; Jian Ding; Cheng Luo*; Jian Li*; Min Huang*; Meiyu Geng*, JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification, Cancer Research, 2015, 75(22): 4923~4936.

10. Huang Huang; Wenhua Chen; Yong Xu; Jian Li*, I−/TBHP catalyzed Csp3–N/Csp2–N bond formation via oxidative coupling with benzophenone imine in water, Green Chemistry, 2015, 17(10): 4715~4719.